報價延遲最少15分鐘:2025/11/15 21:11 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
66.39 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.21/-1.81
|
|
企業價值
14.26B
|
| 資產負債 |
|
每股賬面淨值
-10.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.30M
|
|
每股收益
0.05
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/15 21:11 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
